The founder of a cannabinoid drinks company who swapped her evening tipple for cannabis with a twist talks to Cannabis Health.
When Alana Burstein, founder and president of Viv & Oak, gave up alcohol five years ago, she was looking for something else she could enjoy while socialising and unwinding, and came up with the idea to replace the alcohol in wine with something she believes is healthier: cannabinoids.
“I was a wine drinker, and I wanted to mimic that socially shared experience,” she says. “I thought there’s got to be a better way.”
“I took my idea, and met some really good people who helped me fulfil what I wanted to do.”
This is how Viv & Oak was born, offering Zinfandel wine, derived from California grapes that have been de-alcoholised and blended with THC and CBD.
“I decided to use CBD for the healthy and therapeutic benefits for the body, to take the edge off at the end of the day without getting you high. We do varieties with THC in it, but the CBD is also doing extremely well.”
The drinks are low sugar and calories, she adds, and the drinks containing THC take around 15 minutes to start having an effect.
Viv & Oak’s products are aimed at women much like Burstein, who want to “take the edge off” at the end of the day, she says.
“We’re targeting women aged 35 to 55 who want to drink less alcohol,” she says. “We’re going after soccer moms, females diving into cannabis over alcohol, especially those with children, dealing with their children at home over lockdown.”
“A lot of women don’t want that high effect, but want therapeutic energy, or for women who had a glass of wine before bed, this is an alternative.
“It definitely helps you sleep, and keeps you asleep, whereas alcohol keeps you disrupted.”
Burstein lives in Toronto, but Viv & Oak is based in California, where she says the market is especially keen to find low-sugar, low-calorie CBD products. If the business operated in Canada, Burstein wouldn’t be able to package the wine as she does in California, she says, where there’s also a much bigger market.
“Cannabis is more acceptable here all round,” she says, adding that she’s currently targeting the market in Toronto, too.
Burnstein would like to see her wines containing CBD in stores within the next year or two, and plans on creating more CBD varieties.
Also on her to-do list is coming up with single serve cup versions for on-the-go customers.
“Everything is always changing, so we’re trying to keep up with demand,” she says. “I’m always working to be more creative and innovative – that’s really important in such a fast-moving industry,”
One of the biggest obstacles, she says, is distribution, and she wants to expand from online-only.
“We see home delivery as being the home run here,” she says.
“Our target market wants a beautifully packaged bottle at the click of a button, delivered to their door when they have their girlfriends over.”
As far as Burstein’s personal journey with alcohol goes – she doesn’t miss it.
“I find this is way better alternative for so many reasons, much calmer and therapeutic, and it gets my creativity going.
“Me and alcohol just didn’t get along, it didn’t work for me. As cannabis started becoming more legal and accepted, I thought, this could be a solution for me and so many others that struggle with alcohol.
“We’re not trying to keep up with wine brands, we’re simply an alternative for people who don’t want to drink alcohol for whatever reason, whether they can’t or don’t want to, or are taking a break from it.”
Meet the MEDA family: The smart way to drink
MEDA, the premium CBD functional wellness drink brand, founded by Adam Feldheim, has extended its range of products as part of an ambitious growth strategy.
The full range now incorporates NO-LO mixers and a new ready-to-pour vodka Espresso Medatini, as well as its original functional wellness drinks.
Feldheim, an entrepreneur with almost 20 years’ experience in corporate finance and global market research, discovered the benefits of CBD as part of a balanced lifestyle in his native California.
Identifying a gap in the market, pairing CBD with nootropics, adaptogens and other nutrients to promote wellness and wellbeing, MEDA was born in January 2019. In its first year of business MEDA has worked tirelessly to develop a premium lifestyle brand that provides targeted and game- changing wellness.
The CBD market, already mainstream in the USA, is currently valued at just over £325 million in the UK and predicted to increase to £1 billion by 2025.
The benefits of cannabinoids like CBD are extensive, with the primary function of supporting endocannabinoid health, helping those who consume it to achieve homeostasis.
MEDA has worked with Mary Biles and Clarsissa Lenherr, a respected CBD expert and leading nutritionist respectively, enabling the brand to be an informative voice in the emerging CBD and wellness space.
Focussing specifically on functionality and balance, each of its wellness drinks are made up of a unique set of ingredients
that are recognised for their functionalities. Examples of this include the use of Ashwagandha and Lemon balm in ‘Calm’, to help lower cortisol and reduce stress; In ‘Recover,’ Turmeric and Vitamin D are added to improve muscle recovery and aid immunity.
Balance is also at the heart of the new NO-LO range. When mixed with spirits, MEDA NO-LO drinks provide a conscious alternative to the high sugar and calorific mixers that are commonly used, as well as the combination of CBD and alcohol providing additional benefits. The MEDA NO- LO mixers can also be enjoyed on their own, as a non- alcoholic drink.
Pre-bottled with premium vodka and ready-to-drink, The Medatini represents a twist on London’s most popular cocktail yet contains only half the sugar and calories of a standard espresso martini.
Created by Feldheim in collaboration with Luís Simões, former Beverage Director at Annabel’s in Mayfair, it guarantees a perfect pour and can be served traditionally in a martini glass or, for the summer, over ice as a refreshing, caffeinated CBD cocktail. Currently the range is available online directly via MEDA and in retail stockists including Planet Organic, As Nature Intended, Revital and Daylesford Organic.
It is also served in some of London’s leading bars and restaurants including The Birley Group, The Ivy Collection, Chiltern Firehouse, The Arts Club, Park Chinois and Aqua Shard. The range is made in the UK and is vegan, with fully recyclable packaging.
An ambitious brand, led by Feldheim along with a team of seasoned advisors, MEDA is set for a pivotal year ahead with further product launches, lifestyle partnerships and collaborations to be announced.
The team also have plans to release Mixology Experience packages which customers will be able to order from the website for same day delivery in London and next day delivery across the UK, perfect for the boom in at-home entertaining.
These will include MEDA NO-LO mixers, alcohol spirits, and garnishes for you to create your very own bar experience at home.
To buy the Functional Wellness range, MEDA NO-LO or the Espresso Medatini, or for more information please visit: medahuman.com/shop @medahuman
Australia welcomes ruling on CBD products
Low-dose CBD products can go on sale over the counter in Australia from next year – but no smoking, vaping, topicals.
The Therapeutic Goods Administration (TGA) announced its decision on Tuesday 9 September, to make registered low-dose CBD products available for sale in Australian pharmacies from next year, as a Schedule 3 drug.
The decision had no major changes from the initial proposal made in April 2020 and opens the door for companies to apply for registration of their applicable products to be available over the counter in late 2021-2022.
The new regulations will allow the sale of registered pure CBD products (with 2% or less other cannabinoids) to adults in packets containing up to 1,800mg of CBD. This is 30 days supply of the recommended maximum daily dose of 60mg.
The announcement limited the products available to oral, oral mucosal and sublingual formulations only, ruling out vaping or topical cream products.
There was also an additional requirement that products be packaged securely and advertising to the general public will not be allowed.
Australian medical cannabis market experts, FreshLeaf Analytics, welcomed the decision, managing director, Cassandra Hunt, commented: “This will be the biggest thing to happen in the industry since legalisation of medicinal cannabis. We expect it will result in more Australians benefiting from the healing properties of cannabis and will reduce the number of people seeking products through unregulated illicit channels. The next challenge will be getting products in the market as quickly and cost effectively as possible.”
There are currently 17 low-dose CBD products available via the SAS-B and Authorised Prescriber pathways in Australia, with CBD products currently making up about 40 percent of all medicinal cannabis prescriptions.
FreshLeaf expects the over-the-counter CBD market to grow rapidly and exceed $200 million of revenue.
“We believe low dose CBD will become the largest market in Australia for cannabis products, quickly generating revenue in the hundreds of millions of dollars. There is a significant opportunity here for product companies to supply high quality, low cost medicine to pharmacies,” said Tim Drury, director of Southern Cannabis Holdings.
Pharmacists will still need to consult with consumers to ensure they are aware of potential drug-drug interactions as CBD can affect the way certain other medications are metabolised.
Dr Melissa Benson, advisory board member of Applied Cannabis Research said: “This is a win for supporting further clinical research in the area of low dose CBD medicines. It could also promote greater safety for patients if it leads to less use of illicit CBD products, which can expose patients to potential harms associated with unregulated products including contamination with heavy metals, pesticides and the like.”
However, Dr Mark Hardy, addiction specialist and CA Clinics medical advisory board member added: “This is a welcome move but it’s important to note that the effects of low-dose CBD may be negligible for many patients.
“Patients seeking treatment for chronic conditions that may benefit from medicinal cannabis may require higher dosages or other cannabinoids such as THC and should therefore consult their GP before taking these products, even in small amounts.”
The proposed implementation date has moved to 1 June 2021.
Home comforts – are CBD furnishings the next big thing?
The emerging market for CBD products offers major growth opportunities in the home furnishings industry, experts have said.
During Furniture Today’s Bedding Conference which was live streamed in the US, panelists introducing CBD products to the home furnishings marketplace, said they see the CBD category growing substantially in the years ahead.
Scott Carr, Malouf’s marketing director, said interest in CBD is on the upswing.
There are 6.4 million online searches for “CBD” or “cannabidiol” per month, and the US market for CBD products is projected to hit $20 billion by 2024. The global cannabis market is projected to be more than $40 billion by 2024, he said.
Malouf sees strong growth opportunities in the segment, which it entered earlier this year with a CBD pillow, offered with three options.
Susan Mathes, vice president of brand relations for Therapedic, the first Top 10 bedding producer to offer a CBD mattress line, also sees a major upside for the segment.
“Scientific studies show CBD benefits a number of conditions including pain, anxiety and sleep disorders,” she said.
“CBD products are gaining significant market share in all forms due to its benefits related to well-being.”
Mathes also said the category is a natural for bedding.
“With CBD being known to help with restlessness, calming and insomnia,” she said, “how could it not be good to put in a mattress?”
Therapedic’s b-calm mattress line features CBD infused in the quilt fabric and in a layer of graphite latex. It is available flat-packed or roll-packed, and offers several strong talking points for retail sales associates.
Mathes has a family tie to the CBD field: Her husband, Barry, is involved in the manufacture of personal care CBD products for consumer products customers, and his work gave her insight into the field.
Also participating in the panel discussion was Shane Mutter, CEO of Seed2System, a CBD supplier based in Colorado.
“We start with premium seeds and we farm using organic practices,” he said.
“Our vertical supply chain yields consistent results with sustainable and scalable growth.”
He said Seed2System boasts a full line of CBD products, including tinctures, topical salves, edible salves, and gummies and honey sticks, with products for the bath, body and men’s categories.
Prior to his time in the hemp industry, Mutter was president and CEO of his family’s 80-plus-year-old home furnishings business on the outskirts of the French Quarter of New Orleans, Doerr Furniture.
Mutter said CBD’s appeal is broad, noting that youths, adults and seniors all benefit from CBD products.
- Cancer survivor claims cannabis oil helped her beat brain tumour
- Labour MPs call for possible regulation of a legalised cannabis market
- CBD in Europe – what does the future look like?
- ‘Failure’ to embrace medical cannabis has caused “preventable deaths” – report
- “I’m not a bad person” – chronically ill woman convicted of growing medical cannabis
- Medical cannabis companies given green light for UK stock market in ‘long overdue’ move
Feature3 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News2 months ago
NHS lines up cannabis medicine manufacturing
News1 week ago
Mum of three-year-old with ‘one in a million’ condition fights for medical cannabis funding
Case Studies6 months ago
CBD oil and fibromyalgia – a case study
Industry1 month ago
Building America’s biggest hemp empire
News2 months ago
Gut health and CBD – study
News2 months ago
Researchers hail CBN breakthrough
News2 weeks ago
Over one million patients eligible for new medical cannabis exemption card